Advertisement

 

 

Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals.

Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals.
Author Information (click to view)

Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus Nordwall J, Johnson M, Vjecha MJ, Kelleher AD, Emery S,


Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus Nordwall J, Johnson M, Vjecha MJ, Kelleher AD, Emery S, (click to view)

Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus Nordwall J, Johnson M, Vjecha MJ, Kelleher AD, Emery S,

Advertisement

Scientific reports 2017 09 077(1) 10934 doi 10.1038/s41598-017-11405-8

Abstract

Liver disease is one of the main contributors to the increased levels of morbidity and mortality seen in the HIV-1-infected, ART-treated population. Circulating miRNAs, particularly those located inside extracellular vesicles, are seen as promising biomarkers for a number of human disease conditions, including liver-related diseases. Here, we show that serum levels of miR-122 and miR-200a are greater in HIV/HCV co-infected individuals compared to HIV-1 mono-infected individuals. We also show that miR-122 and miR-200a are elevated in ART-treated, HIV-1-infected individuals prior to the development of fatal liver disease, suggesting that these miRNA may have some potential clinical utility as biomarkers. While this study is hypothesis generating, it shows clearly that both miR-122 and miR-200a are promising novel biomarkers for liver disease in the ART-treated, HIV-1-infected population.

Submit a Comment

Your email address will not be published. Required fields are marked *

sixteen − nine =

[ HIDE/SHOW ]